KR960700261A - 2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives) - Google Patents

2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives)

Info

Publication number
KR960700261A
KR960700261A KR1019950702963A KR19950702963A KR960700261A KR 960700261 A KR960700261 A KR 960700261A KR 1019950702963 A KR1019950702963 A KR 1019950702963A KR 19950702963 A KR19950702963 A KR 19950702963A KR 960700261 A KR960700261 A KR 960700261A
Authority
KR
South Korea
Prior art keywords
amino
compound
alkyl
ribofuranuronamide
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019950702963A
Other languages
English (en)
Korean (ko)
Inventor
마이클 그레그썬
배리 에드워드 에이러스
조지 블랜치 에완
프랭크 엘리스
죤 나이트
Original Assignee
앨렌 헤스케쓰
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앨렌 헤스케쓰, 글락소 그룹 리미티드 filed Critical 앨렌 헤스케쓰
Publication of KR960700261A publication Critical patent/KR960700261A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019950702963A 1993-01-20 1994-01-18 2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives) Abandoned KR960700261A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds
GB9301000.7 1993-01-20
PCT/EP1994/000145 WO1994017090A1 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives

Publications (1)

Publication Number Publication Date
KR960700261A true KR960700261A (ko) 1996-01-19

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702963A Abandoned KR960700261A (ko) 1993-01-20 1994-01-18 2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives)

Country Status (29)

Country Link
US (2) US5925624A (Direct)
EP (1) EP0680488B1 (Direct)
JP (1) JP3768232B2 (Direct)
KR (1) KR960700261A (Direct)
CN (1) CN1043997C (Direct)
AP (1) AP457A (Direct)
AT (1) ATE164849T1 (Direct)
AU (1) AU679714B2 (Direct)
CA (1) CA2153688A1 (Direct)
CZ (1) CZ187995A3 (Direct)
DE (1) DE69409503T2 (Direct)
DK (1) DK0680488T3 (Direct)
EC (1) ECSP941104A (Direct)
ES (1) ES2117249T3 (Direct)
FI (1) FI953489L (Direct)
GB (1) GB9301000D0 (Direct)
HU (1) HU211914A9 (Direct)
IL (1) IL108372A (Direct)
IS (1) IS4121A (Direct)
NO (1) NO305603B1 (Direct)
NZ (1) NZ259880A (Direct)
PE (1) PE54194A1 (Direct)
PL (1) PL309975A1 (Direct)
RU (1) RU2129561C1 (Direct)
SI (1) SI9400021A (Direct)
SK (1) SK281229B6 (Direct)
TW (1) TW267168B (Direct)
WO (1) WO1994017090A1 (Direct)
ZA (1) ZA94335B (Direct)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000963B1 (ru) * 1995-05-30 2000-08-28 Рон-Пуленк Роре С.А. Производные 2-азабицикло[2.2.1]гептана, способ их получения и их применение
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
KR100568658B1 (ko) * 1998-02-26 2006-04-07 아벤티스 파마슈티칼스 인크 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
TR200003513T2 (tr) 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1313861A (zh) 1998-06-23 2001-09-19 葛兰素集团有限公司 2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
NZ522076A (en) * 2000-04-25 2005-08-26 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE60225141T2 (de) * 2001-07-06 2009-03-05 Topigen Pharmaceuticals Inc., Montreal Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren
HU229504B1 (hu) * 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
MXPA04004966A (es) 2001-11-27 2006-03-21 Anadys Pharmaceuticals Inc Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
KR20050067384A (ko) * 2002-08-15 2005-07-01 씨브이 쎄러퓨틱스, 인코포레이티드 부분적 또는 완전한 ａ1 아데노신 수용체의 작용제
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
JP5314283B2 (ja) * 2004-10-29 2013-10-16 トピジェン・ファーマシューティカルズ・インコーポレーテッド アレルギーおよび新生物細胞増殖を治療するための、アンチセンスオリゴヌクレオチド
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7560544B2 (en) 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
AU2006318260B2 (en) 2005-11-21 2012-05-17 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TWI418561B (zh) 2006-06-22 2013-12-11 Anadys Pharmaceuticals Inc ５-胺基-３-（３’-去氧-β-Ｄ-核糖呋喃糖基（ｒｉｂｏｆｕｒａｎｏｓｙｌ））-噻唑并〔４，５-ｄ〕嘧啶-２，７-二酮之前藥
US7528115B2 (en) 2006-07-18 2009-05-05 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8796241B2 (en) 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
TW201129565A (en) 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
AR090253A1 (es) 2012-03-05 2014-10-29 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (Direct) 2013-07-12 2018-07-21
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
NO2717902T3 (Direct) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
JP7430892B2 (ja) * 2016-08-10 2024-02-14 株式会社スリーボンド エポキシ樹脂組成物およびこれを含む導電性接着剤
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
AU582359B2 (en) * 1984-04-18 1989-03-23 Nelson Research & Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
PT86660B (pt) * 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
DE3810551A1 (de) * 1987-04-06 1988-11-03 Sandoz Ag Neue ribofuranuronsaeure-derivate
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
IE903747A1 (en) * 1989-10-19 1991-04-24 Searle & Co Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
IL108372A (en) 1998-06-15
IS4121A (is) 1994-07-21
JP3768232B2 (ja) 2006-04-19
JPH08505864A (ja) 1996-06-25
GB9301000D0 (en) 1993-03-10
NZ259880A (en) 1996-11-26
CA2153688A1 (en) 1994-08-04
SK91895A3 (en) 1996-04-03
NO305603B1 (no) 1999-06-28
AP457A (en) 1996-02-01
FI953489A0 (fi) 1995-07-19
SI9400021A (en) 1994-09-30
ZA94335B (en) 1994-10-24
DE69409503D1 (de) 1998-05-14
FI953489A7 (fi) 1995-09-13
AP9400613A0 (en) 1994-01-31
PL309975A1 (en) 1995-11-13
NO952872L (no) 1995-09-13
SK281229B6 (sk) 2001-01-18
IL108372A0 (en) 1994-04-12
US5889178A (en) 1999-03-30
ATE164849T1 (de) 1998-04-15
AU679714B2 (en) 1997-07-10
RU2129561C1 (ru) 1999-04-27
TW267168B (Direct) 1996-01-01
DE69409503T2 (de) 1998-08-06
DK0680488T3 (da) 1999-01-25
NO952872D0 (no) 1995-07-19
ES2117249T3 (es) 1998-08-01
HU211914A9 (en) 1996-01-29
WO1994017090A1 (en) 1994-08-04
CN1043997C (zh) 1999-07-07
EP0680488A1 (en) 1995-11-08
FI953489L (fi) 1995-09-13
US5925624A (en) 1999-07-20
AU5885194A (en) 1994-08-15
ECSP941104A (es) 1994-12-15
CZ187995A3 (en) 1996-01-17
EP0680488B1 (en) 1998-04-08
CN1119440A (zh) 1996-03-27
PE54194A1 (es) 1995-01-06

Similar Documents

Publication Publication Date Title
KR960700261A (ko) 2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives)
RU95122754A (ru) Производные 2,6-диаминопурина и способ их получения, способ производства лекарства, фармацевтический состав и способ лечения
RU2191189C2 (ru) Производные замещенного пуринила, обладающие иммуномодуляторной активностью, фармацевтическая композиция и способ замедления роста опухоли
US7427606B2 (en) Method to reduce inflammatory response in transplanted tissue
EP1027363B1 (en) Adenosine a1-receptor agonists
ATE31537T1 (de) Peptidderivate mit polyzyklischer stickstoffstruktur, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR920000788A (ko) 폴리펩티드 화합물 및 그것의 제조방법
KR970042553A (ko) 캠프토테신 유도체
DE68926403D1 (de) Peptid-Verbindungen, deren Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung
KR970701698A (ko) 프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists)
DE69015244D1 (de) Peptidverbindungen, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
DE69123697D1 (de) Peptidverbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
KR920006335A (ko) 안지오텐신 ⅱ수용체 길항제
OA09354A (fr) "Nouveaux dérivés de l'amino pipéridine, de l'amino pyrrolidine et de l'amino perhydroazépine, leurs procédés de préparation, les compositions pharmaceutiques qui les contiennent".
KR970707098A (ko) 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
CA2340156A1 (en) .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
ATE74603T1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
RU95113148A (ru) Производное 2-(2-амино-1,6-дигидро-6-оксопурин-9-ил)-метокси-1,3-пропандиола
EP0467856A3 (en) Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases
ATE100464T1 (de) Peptid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
RU2003134629A (ru) Соединения цефема
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
DE68922053D1 (de) Pyridoindolderivate und Verfahren zu ihrer Herstellung.
DE3853493D1 (de) Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20001230

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20011010

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee